SynthesisBMC cancer2025
Immunotherapy combined with radiotherapy in the treatment of lung cancer: a meta-analysis of therapeutic effectiveness, safety considerations, and abscopal effect.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC: the phase II RECLAIM trial.Journal for immunotherapy of cancer · 2026Trial
- Global hotspots and trends of stereotactic radiotherapy for pancreatic cancer: a bibliometric analysis and visual analysis from 2015 to 2025.Translational cancer research · 2026Article
- Navigating the immunosuppressive abyss: current hurdles and innovative breakthroughs in neoadjuvant immunotherapy for osteosarcoma.Frontiers in immunology · 2026Review
- Nrf2 functions as a biomarker and therapeutic target in lung cancer based on bibliometric analysis and molecular mechanisms.Discover oncology · 2025Article
- Efficacy and Safety of Sintilimab in Combination With Anlotinib and Chemoradiotherapy as First-Line Treatment for Driver Gene-Negative Oligometastatic Non-small Cell Lung Cancer: A Real-World Cohort Study.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeWith the escalating global incidence and mortality of lung cancer, immunotherapy has achieved modest success while facing persistent challenges. The immunomodulatory effect of radiotherapy has gradually gained attention, especially the abscopal effect observed in the combination of radiotherapy and immunotherapy. Although mechanistically controversial, its clinical significance in lung cancer treatment is noteworthy. Therefore, this study aims to delve into the therapeutic differences between immunotherapy using immune checkpoint inhibitors (ICI) combined with radiotherapy (RT) and traditional immunotherapy alone, aiming to provide scientific evidence for optimizing lung cancer treatment strategies, improving patient outcomes, and enhancing survival rates.
methodsLiterature searches were conducted in PubMed, Embase, Web of Science, and the Cochrane Library up to 26 March 2024. Heterogeneity, sensitivity analysis, forest plots, clipping plots, and publication bias were analysed using RevMan5.4 and Stata 12.0.
resultsThis meta-analysis included 19 articles, encompassing 5109 lung cancer patients in the ICI + RT group and 4686 patients in the ICI group. Meta-analysis revealed that the progression-free survival (PFS) (HR = 0.68, 95%CI [0.62-0.75], p < 0.00001) and overall survival (OS) (HR = 0.70, 95%CI [0.62-0.79], p < 0.00001) of lung cancer patients in the ICI + RT treatment group were longer than those in the ICI treatment group, and ICI + RT or ICI treatment for lung cancer patients did not affect adverse events (OR = 1.09, 95%CI [0.80-1.50], p > 0.05) or death (HR = 1.03, 95%CI [0.30-3.57], p < 0.05).The subgroup analysis showed that within the PFS group, RCT (HR = 0.73, 95%CI [0.62-0.85], p < 0.00001), Non-RCT (HR = 0.61, 95%CI [0.49-0.76], p < 0.00001), Nivolumab (HR = 0.57, 95%CI [0.46-0.71], p < 0.00001), Pembrolizumab (HR = 0.67, 95%CI [0.57-0.80], p < 0.00001), stating ICI or during ICI (HR = 0.69, 95%CI [0.61-0.79], p < 0.00001), during ICI (HR = 0.70, 95%CI [0.58-0.85], p < 0.001), squamous (HR = 0.57, 95%CI [0.41-0.79], p < 0.001), Non-squamous (HR = 0.63, 95%CI [0.47-0.83], p < 0.001), smoking (HR = 0.46, 95%CI [0.39-0.95], p < 0.05), no smoking or smoking history (HR = 0.73, 95%CI [0.63-0.92], p < 0.01), ECOG = 0 (HR = 0.53, 95%CI [0.37-0.75], p < 0.01), ECOG > = 1 (HR = 0.61, 95%CI [0.45-0.83], p < 0.01) were significant, male (HR = 0.56, 95%CI [0.44-0.70], p < 0.0001), female (HR = 0.74, 95%CI [0.52-1.05], p > 0.05) were only significant in males, PD-1 high expression (HR = 0.92, 95%CI [0.48-1.78], p > 0.05), PD-1 low expression (HR = 0.61, 95%CI [0.40-0.92], p < 0.05) were significant only in PD-1 low expression; within the OS group, RCT (HR = 0.65, 95%CI [0.55-0.76], p < 0.00001), Non-RCT (HR = 0.77, 95%CI [0.65-0.91], p < 0.01), Nivolumab (HR = 0.73, 95%CI [0.54-0.99], p < 0.05), Pembrolizumab (HR = 0.64, 95%CI [0.55-0.75], p < 0.00001), stating ICI or during ICI (HR = 0.74, 95%CI [0.64-0.86], p < 0.00001), during ICI (HR = 0.65, 95%CI [0.52-0.82], p < 0.001), Smoking (HR = 0.61, 95%CI [0.28-0.75], p < 0.01), No smoking or smoking history (HR = 0.76, 95%CI [0.62-0.86], p < 0.001) were significant, male (HR = 0.59, 95%CI [0.44-0.78], p < 0.0001), female (HR = 1.01, 95%CI [0.68-1.48], p > 0.05) were only significant in males, PD-1 high expression (HR = 0.53, 95%CI [0.22-1.26], p > 0.05), PD-1 low expression (HR = 0.60, 95%CI [0.39-0.94], p < 0.05) were significant only in PD-1 low expression, ECOG = 0 (HR = 0.51, 95%CI [0.31-0.82], p < 0.01), ECOG > = 1 (HR = 0.80, 95%CI [0.52-1.23], p > 0.05) were significant only in ECOG = 0.
conclusionThe results of this study indicate that the combination of ICI and RT significantly prolongs the Progression-Free-Survival and Overall Survival of lung cancer patients compared to the use of ICI alone, demonstrating a certain therapeutic advantage across different subgroups. This finding provides robust evidence supporting the widespread adoption of ICI+RT combination therapy for lung cancer, potentially leading to more effective treatment strategies, improved patient outcomes, and higher survival rates.
trial registrationhttps://www.crd.york.ac.uk/prospero/ , identifier CRD42024544343.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.